Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoplus vs Lipofundin in Acute Lung Injury
NCT01814956Phase 4Terminated
- Sponsor
- B. Braun
- Start
- Mar 2013
- Primary completion
- May 2015
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Lipidem in acute lung injury (ALI) (2 arms), sponsored by B. Braun. Primary endpoint: Change in blood oxygenation (PaO2/FiO2 ratio). Started Mar 2013; status: terminated.
02
Drugs
Lipidem
03
Conditions
acute lung injury (ALI)
Beyond the preview
Go deeper on NCT01814956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01814956.